JP2011503207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503207A5 JP2011503207A5 JP2010534249A JP2010534249A JP2011503207A5 JP 2011503207 A5 JP2011503207 A5 JP 2011503207A5 JP 2010534249 A JP2010534249 A JP 2010534249A JP 2010534249 A JP2010534249 A JP 2010534249A JP 2011503207 A5 JP2011503207 A5 JP 2011503207A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- cell
- pim
- cells
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 31
- 210000000130 stem cell Anatomy 0.000 claims 17
- 239000013598 vector Substances 0.000 claims 17
- 230000014509 gene expression Effects 0.000 claims 14
- 239000000126 substance Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 210000001519 tissue Anatomy 0.000 claims 12
- 210000002216 heart Anatomy 0.000 claims 11
- 210000000056 organ Anatomy 0.000 claims 11
- 210000002064 heart cell Anatomy 0.000 claims 10
- 206010021143 Hypoxia Diseases 0.000 claims 9
- 210000004165 myocardium Anatomy 0.000 claims 9
- 210000004204 blood vessel Anatomy 0.000 claims 8
- 230000000747 cardiac effect Effects 0.000 claims 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims 6
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 claims 6
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims 6
- 102000004987 Troponin T Human genes 0.000 claims 6
- 108090001108 Troponin T Proteins 0.000 claims 6
- 108010051583 Ventricular Myosins Proteins 0.000 claims 6
- 210000000663 muscle cell Anatomy 0.000 claims 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- 210000005003 heart tissue Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- 206010002660 Anoxia Diseases 0.000 claims 3
- 241000976983 Anoxia Species 0.000 claims 3
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims 3
- 230000007953 anoxia Effects 0.000 claims 3
- 229940124447 delivery agent Drugs 0.000 claims 3
- 208000018875 hypoxemia Diseases 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 2
- 208000012339 Vascular injury Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 210000004507 artificial chromosome Anatomy 0.000 claims 2
- 108700000711 bcl-X Proteins 0.000 claims 2
- 102000055104 bcl-X Human genes 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000005779 cell damage Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001953 sensory effect Effects 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000002460 smooth muscle Anatomy 0.000 claims 2
- 210000001032 spinal nerve Anatomy 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 210000005166 vasculature Anatomy 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 1
- 108010017121 Proto-Oncogene Proteins c-pim-1 Proteins 0.000 claims 1
- 102000004433 Proto-Oncogene Proteins c-pim-1 Human genes 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 210000004504 adult stem cell Anatomy 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 108010007734 bcl-Associated Death Protein Proteins 0.000 claims 1
- 102000007348 bcl-Associated Death Protein Human genes 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 1
- 230000003293 cardioprotective effect Effects 0.000 claims 1
- 230000007348 cell dedifferentiation Effects 0.000 claims 1
- 230000037326 chronic stress Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002308 embryonic cell Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000007755 survival signaling Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000005167 vascular cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98875307P | 2007-11-16 | 2007-11-16 | |
| US9169808P | 2008-08-25 | 2008-08-25 | |
| PCT/US2008/083693 WO2009065080A1 (en) | 2007-11-16 | 2008-11-14 | Compositions and method for manipulating pim-1 activity in circulatory system cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014154915A Division JP5795670B2 (ja) | 2007-11-16 | 2014-07-30 | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503207A JP2011503207A (ja) | 2011-01-27 |
| JP2011503207A5 true JP2011503207A5 (enExample) | 2012-01-05 |
Family
ID=40639186
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534249A Pending JP2011503207A (ja) | 2007-11-16 | 2008-11-14 | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
| JP2014154915A Expired - Fee Related JP5795670B2 (ja) | 2007-11-16 | 2014-07-30 | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014154915A Expired - Fee Related JP5795670B2 (ja) | 2007-11-16 | 2014-07-30 | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US8617534B2 (enExample) |
| EP (1) | EP2209889B1 (enExample) |
| JP (2) | JP2011503207A (enExample) |
| CA (1) | CA2705862C (enExample) |
| WO (1) | WO2009065080A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2814513B1 (en) * | 2012-02-14 | 2017-12-20 | The Regents of The University of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| AU2018283372B2 (en) | 2017-06-16 | 2024-06-13 | Avery Therapeutics, Inc. | Three dimensional tissue compositions and methods of use |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| CN108913655B (zh) * | 2018-07-16 | 2022-07-15 | 浙江大学 | 基于多能干细胞技术建立“人源性”心肌肥大模型的方法 |
| WO2020081604A2 (en) * | 2018-10-15 | 2020-04-23 | Avery Therapeutics, Inc. | Cell-free compositions and methods for restoration or enhancement of tissue function |
| MY209860A (en) | 2020-02-13 | 2025-08-07 | Tenaya Therapeutics Inc | Gene therapy vectors for treating heart disease |
| EP4209341A4 (en) * | 2020-09-04 | 2024-10-23 | Dexerials Corporation | CONDUCTIVE LAMINATED PRODUCT, OPTICAL DEVICE USING SAME, AND MANUFACTURING METHOD FOR CONDUCTIVE LAMINATED PRODUCT |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| WO1998010085A2 (en) * | 1996-09-05 | 1998-03-12 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
| US20040132190A1 (en) | 1995-02-28 | 2004-07-08 | The Regents Of The University Of California | Gene therapy for myocardial ischemia |
| US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
| US5869037A (en) * | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
| US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| ATE198910T1 (de) | 1996-10-17 | 2001-02-15 | Oxford Biomedica Ltd | Retrovirale vektoren |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
| JP2000516641A (ja) | 1997-07-02 | 2000-12-12 | エスディージー インコーポレイテッド | 診断および治療用途の目標指向性リポソーム構成物 |
| JP2001517433A (ja) | 1997-09-24 | 2001-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非霊長類レンチウイルスベクターおよびパッケージングシステム |
| DK1895010T3 (da) | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US6867348B1 (en) * | 1999-12-16 | 2005-03-15 | Xenogen Corporation | Methods and compositions for screening for angiogenesis modulating compounds |
| US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| WO2002057413A2 (en) * | 2001-01-18 | 2002-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta pkc |
| JP2005501802A (ja) * | 2001-01-23 | 2005-01-20 | ボストン サイエンティフィック コーポレイション | 虚血心筋を処置するための限局性心筋注入方法 |
| US20030003582A1 (en) | 2001-05-08 | 2003-01-02 | Tranzyme, Inc. | Trans-viral vector mediated gene transfer to the retina |
| US7732199B2 (en) * | 2001-07-12 | 2010-06-08 | Geron Corporation | Process for making transplantable cardiomyocytes from human embryonic stem cells |
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| RU2305708C2 (ru) | 2001-10-02 | 2007-09-10 | Энститю Клейтон Де Ля Решерш | Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение |
| US20040258669A1 (en) * | 2002-11-05 | 2004-12-23 | Dzau Victor J. | Mesenchymal stem cells and methods of use thereof |
| EP1624073A4 (en) * | 2003-04-03 | 2006-05-17 | Oncorex Inc | DRUG |
| US20060246047A1 (en) * | 2003-06-24 | 2006-11-02 | Masaya Imoto | Peptide wirh apoptosis-inhibiting activity |
| US7135339B2 (en) | 2003-11-20 | 2006-11-14 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) |
| US20070077286A1 (en) | 2003-12-24 | 2007-04-05 | Tsutomu Ishihara | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| US20050266067A1 (en) | 2004-03-02 | 2005-12-01 | Shiladitya Sengupta | Nanocell drug delivery system |
| WO2006014035A1 (en) | 2004-08-06 | 2006-02-09 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
| AU2005304708B2 (en) * | 2004-11-08 | 2012-01-19 | The Johns Hopkins University | Cardiac stem cells |
| CA2609937A1 (en) * | 2005-05-27 | 2006-11-30 | The Hospital For Sick Children | Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| US20120128631A1 (en) | 2009-05-19 | 2012-05-24 | San Diego State University (SDSU) Foundation, dba San Diego State University (SDSU) Research | Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence |
-
2008
- 2008-11-14 JP JP2010534249A patent/JP2011503207A/ja active Pending
- 2008-11-14 US US12/742,871 patent/US8617534B2/en active Active
- 2008-11-14 CA CA2705862A patent/CA2705862C/en active Active
- 2008-11-14 WO PCT/US2008/083693 patent/WO2009065080A1/en not_active Ceased
- 2008-11-14 EP EP08850768.6A patent/EP2209889B1/en active Active
-
2013
- 2013-11-18 US US14/082,760 patent/US20140234265A1/en not_active Abandoned
-
2014
- 2014-07-30 JP JP2014154915A patent/JP5795670B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-23 US US15/078,854 patent/US20160324936A1/en not_active Abandoned
-
2018
- 2018-08-16 US US16/104,047 patent/US20190060417A1/en not_active Abandoned
-
2021
- 2021-03-31 US US17/219,749 patent/US20210322522A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503207A5 (enExample) | ||
| ES2401608T3 (es) | Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes | |
| Bhang et al. | Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells | |
| US20150139952A1 (en) | Methods, compositions, cells, and kits for treating ischemic injury | |
| US10174287B2 (en) | Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof | |
| EP4552690A2 (en) | Immortalized cardiac stem cells for cardiac repair | |
| Ohnishi et al. | Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure | |
| Cao et al. | Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow–induced pulmonary arterial hypertension in rabbits | |
| Wang et al. | Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway | |
| US20200131479A1 (en) | Preparation method of human-derived cardiac stem cell spheroid and use thereof | |
| KR20190050277A (ko) | 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물 | |
| Feng et al. | Recent concepts for the roles of progenitor/stem cell niche in heart repair | |
| CA2578815A1 (en) | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment | |
| WO2022196714A1 (ja) | 塩基性繊維芽細胞増殖因子（ｂＦＧＦ）遺伝子が導入されたペリサイト | |
| Lou | Human Pluripotent Stem Cells and Patches Enhance the Repairing Efficacy of Infarcted Cardiac Muscle in Mouse Model | |
| Arsenteva et al. | STEM CELLS APPLICATION TO ENHANCE THE MYOCARDIAL REGENERATION | |
| Lara-Pezzi et al. | Genetic enhancement of cardiac regeneration | |
| Lou | Tissue Engineered Cardiac Muscle Patches with Human Pluripotent Stem Cells Enhance the Repairing Efficacy of Infarcted Cardiac Muscle in Mouse Model | |
| US20210113662A1 (en) | Compositions and methods for the treatment of ischemia and cardiomyopathy | |
| CA2897188A1 (en) | Cd34 stem cell-related methods and compositions | |
| Hendrickx et al. | Cell and Gene Transfer Strategies for Vascularization During Skin Wound Healing | |
| Bruckner et al. | 160: Human Cord Blood Derived Stem Cells Improve Left Ventricular Function and High Energy Phosphates in a Porcine Model of Myocardial Infarction | |
| Wang et al. | Cardiac cell therapy: current status and future trends |